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Background: Cystic fibrosis-associated liver disease (CFLD) is the second cause of mortality in CF. The prevalence is estimated to be 26–45%,
but sensitive diagnostic tools are lacking.
We investigated whether non-invasive liver elastography (Fibroscan) could serve as a screening tool.
Methods: Fibroscan measurements were performed in 66 CF patients. Age-specific cutoff values were determined in a control population (n=59).
The measurements were compared to clinical data, biyearly biochemistry and ultrasound.
Results: Fibroscan was easy to perform in this patient population. There were 14 patients (21%) with abnormal liver stiffness measurements.
Liver stiffness was significantly increased in patients with clinical CFLD (11.2kPa versus 5.1kPa), biochemical CFLD (7.4kPa versus 5.4kPa)
or ultrasonographical CFLD (8.2 versus 4.3kPa) (pb0.02 for all).
Conclusions: Fibroscan is an objective measure and is easy to perform in CF patients, even in children and could provide a valuable tool to detect,
and quantify CFLD.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Cystic fibrosis-associated liver disease; Fibroscan; Screening and diagnosis1. Introduction
Cystic fibrosis associated liver disease (CFLD) is an
upcoming health issue. Emerging during the second decade of
life, it leads to significant morbidity and decreased quality of life
Abbreviations: (ALT), Alanine transaminase; (AST), Aspartate transaminase;
(BMI), Body mass index; (CI), Confidence interval; (CF), Cystic fibrosis; (CFF),
Cystic Fibrosis Foundation; (CFLD), Cystic fibrosis associated liver disease; (FEV1),
Forced expiratory value (one second); (FVC), Forced vital capacity; (GGT), Gamma-
glutamyltransferase; (IQR), interquartile range; (NASH), Non-alcoholic steatohepa-
titis; (PBC), Primary biliary cirrhosis; (PSC), Primary sclerosing cholangitis; (PT),
Prothrombin time; (ROC), Receiver operating characteristic.
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doi:10.1016/j.jcf.2009.08.001in a selected population of young CF patients [1,2]. Moreover, it
is the second most common cause of CF-related mortality [3].
The true prevalence of CFLD is difficult to estimate because
the lack of sensitive and specific diagnostic tools. Based on the
currently available clinical, biochemical and radiologicalmethods
the prevalence of liver disease is estimated at 26 to 45% [1,2,4].
However, these prevalence rates are likely an underestimation
since in older autopsy studies focal biliary cirrhosis is reported in
72% of the cases [5]. Risk factors for the development of CFLD
are also a matter of debate and might include male sex [4]
(although not found in [2,6.7]), CFTRgenotype [4,6,8] (not found
in [1,2,7,9]), age at diagnosis of CF [9] or age at evaluation [6,8],
meconium ileus [1,4,9] (not found in [2,6–9]), severity of
pulmonary disease [7,9] (not found in [1,6]), pancreatic
insufficiency [1,6] and height or weight [7,9] (not found in [6]).
d by Elsevier B.V. All rights reserved.
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of presymptomatic liver disease are needed in order to prevent,
if possible, progression of fibrosis with specific medical
therapies. Furthermore, there is also a continuous search for
minimally invasive, sensitive and quick detection of clinically
important liver disease in order to start screening for esophageal
varices, hepatocellular carcinoma and to prevent other compli-
cations of chronic liver disease. Although liver biopsy remains
the gold standard, limitations are considerable, including patient
discomfort and rare but serious complications such as bleeding
or pneumothorax and a mortality rate of 1/10,000 to 1/12,000
[10]. Moreover, only 1/50,000 of the liver volume is inves-
tigated resulting in sampling error in focally distributed liver
disease as CFLD [10]. Alternative attempts to diagnose and
follow-up the liver disease range from routine biochemistry and
calculated scores to surrogate fibrosis markers in serum, hepatic
clearance tests, various imaging techniques and more recently
the use of non-invasive transient elastography (Fibroscan ®)
[11].
Although more than 55 studies have validated elastography
in patients with hepatitis B, C, primary biliary cirrhosis (PBC)
or sclerosing cholangitis (PSC), non-alcoholic steatohepatitis
(NASH), haemochromatosis and post-transplant (for a meta-
analysis see [12]), only one study included patients with cystic
fibrosis (n=42) [13]. However, this study did not include a
separate analysis of the results in CF patients, did not take into
account the special characteristics of CFLD as the main objec-
tive was to validate the use of the Fibroscan device in children.
Additionally, there are only 3 studies in the paediatric popu-
lation evaluating and validating the Fibroscan in the detection of
liver fibrosis [13–15]. Since CFLD develops early in life and
new cases after 20yr of age are rare [1,2], this mainly paediatric
age group is the most interesting for screening and diagnosing
CFLD. Early diagnosis allows a timely start of ursodeoxycholic
acid therapy [7] or could at least be used to monitor the
evolution of CFLD.
In this study we evaluated the possible role of Fibroscan in
the early detection and screening for CFLD. The aim was to
evaluate the diagnostic accuracy compared to other diagnostic
tools as well as the relation of the liver stiffness to risk factors
for CFLD.
2. Patients and methods
2.1. Patients
Sixty-six CF patients followed at the CF clinic at the
university hospital Gasthuisberg, (Leuven, Belgium) were
scanned consecutively from September 2006 to October 2007.
Because of the lack of published normal paediatric reference
ranges, a control group consisted of fifty-nine children attending
the pulmonology clinic and eighteen healthy hospital staff
members. None had a medical history indicative of any kind of
liver disease or CF according to the patients/parents and to their
medical files.
The study was approved by the local ethics committee and
(parental) informed consent was obtained for all patients.2.2. Fibroscan measurements
Liver stiffness was assessed by transient elastography
(Fibroscan, Echosens, Paris). At least 10 measurements per
patient are obtained, using the standard probe. Median values
and interquartile range (IQR, kPa) are reported (for additional
technical details see [15]). A success-rate of at least 60% was
considered necessary. In the paediatric population special care
was taken in order to make sure there was no A-shaped wave on
the elastogram which indicates an incorrectly accepted (non-
automatically rejected) measurement leading to an overestima-
tion of the stiffness produced by influence of the surrounding
rib bone and soft tissue [13].
2.3. Study design
At the time of the Fibroscan measurements, age, gender and
weight, length, BMI and their respective z-scores (using recent
Flemish reference values) were collected. A clinical question-
naire was filled out by the attending physician recording the
presence or absence of hepatomegaly (N2 cm below costal
margin), splenomegaly, jaundice, icteric sclerae, spider angio-
mata, liver palms, itching or scratch marks, ascites or
encephalopathy. The physician was asked to indicate on a
visual analogue scale what the probability was that the patient
had liver cirrhosis, based on the clinical examination and on
previous biochemistry results.
Clinical liver disease was defined as the presence of
hepatomegaly or splenomegaly [3].
Following data were collected from the CF patient's files: CF
mutations (classified in three groups: F508del homozygous,
two class 1-3 mutations and at least one class 4-5 mutation),
pancreatic state (sufficient: stool elastase above 200 µg/g stool
or insufficient: overt steatorhea without pancreatic enzyme
intake (fat absorption less than 90% on 3 day faecal fat balance)
or stool elastase below 100 µg/g stool), history of meconium
ileus, ursodeoxycholic acid intake (never, persistently or
intermittently), chronic Pseudomonas aeruginosa colonization
(present/absent: repeated isolation of Pseudomonas aeruginosa
(at least 3 positive sputum samples, with at least 1 month
interval over at least a 6 month period) [16]).
Liver tests (AST, ALT, alkaline phosphatase, bilirubin and
gamma-GT) from all CF patients from January 1996 to July
2007 were studied and patients with persistently elevated liver
tests were identified (3–6 months, 1.5 times age-dependent
upper limit of normal). Biochemical liver disease was defined
as the elevation of 2 of these tests [3].
The North-American cystic fibrosis foundation (CFF)
consensus workgroup defines CFLD as the presence of either
clinical or biochemical liver disease [3].
Fibroscan liver disease was defined as a result above the
age-related upper limit of normal liver stiffness. Information
was collected from the clinical files to assess the relation
between the obtained stiffness measurement and:
– the six-monthly CF routine blood analysis closest to the
Fibroscan was assessed (white cell count and differentiation,
Fig. 1. Fibroscan results in controls and CF patients. Boxplots of liver stiffness
(kPa) in the control groups (b12 yr (n=41) and N12 yr (n=18)) and in the CF
groups (b12 yr (n=32) and N12 yr (n=34)).
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electrolytes, albumin, C-reactive protein, AST, ALT, GGT,
PT, vitamin A, vitamin E, 25-OH-vitamin D, haemoglobin
A1C, total cholesterol, IgG and IgE). The AST/platelet ratio
index (APRI score), a non-invasive marker of fibrosis or
cirrhosis, was calculated according to Wai [17].
– the lung function tests (FVC, FEV1 expressed as % predicted
for sex, height and age according to Knudson, within
3 months of the liver stiffness measurement).
– the ultrasound findings (the presence or absence of
hepatomegaly or splenomegaly (compared to age-related
reference variables) and the Williams score, routinely
calculated at our institution [18], within 6 months–1yr of
the liver stiffness measurement). The Williams score
ultrasonographically evaluates the hepatic parenchyma, the
liver edge and the degree of periportal fibrosis. On each of
these three items a score of 1–3 is assigned: the hepatic
parenchyma (1: normal, 2: intermediate abnormal or 3:
irregular), the liver edge (1: smooth or 3: nodular (2 is never
assigned)), the periportal fibrosis (1: absent, 2: moderate, 3:
severe). The scores of each of these items are added into one
number from 3 (perfectly normal) to 9 [18]. Ultrasono-
graphic liver disease was defined as a Williams score of at
least 4/9 (i.e. intermediate coarse to irregular liver paren-
chyma, liver edge nodularity and/or moderate to severe
periportal fibrosis) [18].
– the liver biopsy findings if obtained.
– the presence or absence of esophageal varices if a gastroscopy
was performed within 2yr of the liver stiffness measurement.
2.4. Statistical analysis
SPSS 16.0 for windows (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. All results are expressed as means±
standard deviation. For differences between two continuous
variables in two (or more) groups the Mann-Whitney U (or
Kruskal-Wallis) test was used. To compare categorical variables
Fisher exact test (2-sided) was used. For correlations within a
group the Spearman Rank Correlation coefficient was used. A
p-value b0.05 was considered statistically significant and a p-
value b0.10, was considered as a statistical trend. Shapiro-Wilk
test was used to assess normality of the Fibroscan results in the
control population (a non-significant p-value indicates normal-
ity) and age groups and their specific normal value cutoffs were
defined post hoc using age-liver stiffness scatter plots and
Mann-Whitney U tests.
Sensitivity, specificity, positive predictive likelihood ratio
and negative likelihood ratio were calculated. ROC curves with
95% confidence intervals (CI) were calculated to assess the
diagnostic accuracy for the detection of CFLD.
3. Results
3.1. Control group
The control group (n=59) consisted of 26 male and 33 female
subjects with a mean age of 10.2±3.7yr (41 patients b12 yr, 18patients 12–18yr). Fibroscan results did not differ between males
and females or did not correlate with length, weight, BMI or their
respective z-scores. However, there was an age-dependent
increase in liver stiffness with higher values in the age group
12–18yr (n=18) compared to the age group below 12yr (n=41)
(pb0.0001, see Fig. 1). As liver stiffness measurements were
normally distributed within both groups (b12 yr p=0.474 and
N12 yr p=0.717), the age-specific upper limit of normal value
was determined as the average plus two standard deviations (i.e.
the 98th percentile) andwas 5.63 kPa for theb12 yr control group
and 6.50kPa for the N12 yr control group. As the liver stiffness
measurementswere not significantly different between the control
groups 12–18yr and N18 yr (n=18 in both groups, p=0.815), the
same cut-off was used in the corresponding patient group
(6.50kPa).
3.2. Liver disease in cystic fibrosis
The CF group (n=66) consisted of 36 male and 30 female
patients with a mean age of 13.6±7.8yr (32 patients b12 yr, 24
patients between 12 and 18yr and 10 patients N18 yr, for
baseline characteristics see Table 1). Six patients (9%) had
evidence of clinical CFLD (hepatomegaly or splenomegaly)
and 7 (11%) had evidence of biochemical CFLD. Ultrasonog-
raphy revealed hepatomegaly in 15 (23%) patients and
splenomegaly in 16 patients (24%). 26 patients (39%) had
clinical, biochemical or ultrasonographic CFLD.
3.3. Liver stiffness measurements in cystic fibrosis
The mean stiffness in patients with CF was 5.63±4.02kPa
with an IQR of 1.28±1.01. There were 14 patients (21%) with
abnormal liver stiffness measurements compared to the age-
related normal values (for detailed characteristics of these
patients see Table 2). Of these patients, 5 had clinical CFLD and
4 had evidence of biochemical CFLD. All but one had an
abnormal Williams score (although she had clinical and
biochemical CFLD, patient 1) and 12 had hepatomegaly or
splenomegaly on ultrasound (compared to age-related reference
Table 1
Baseline characteristics, suggested risk factors and relation to liver stiffness measurements.
N (%) Mean±Stdev Liver stiffness
measurement
(kPa) p-value
CFLD definitions
CFLD according to Consensus workgroup definition Yes 11 (17) 8.83±4.79 b0.0002
No 55 (83) 4.99±3.56
US CFLD Yes 23 (36) 8.19±5.96 b0.0001
No 41 (64) 4.27±0.94
Risk factors
Gender Male 36 (55) 5.44±3.00 0.221
Female 30 (45) 5.84±5.02
Genotype group F508del/F508del 40 (60) 6.21±4.37 0.009
2 class1-3 mutation 17 (26) 5.09±4.04
At least one class 4-5 mutation 9 (14) 4.02±0.58
Age at diagnosis 1.6±3.1 −0.466 b0.0002
Age at hepatic work-up 13.6±7.7 0.263 0.033
Meconium ileus Yes 13 (20) 8.15±6.92 0.013
No 53 (80) 5.01±2.67
Pulmonary function FVC (%pred) 90.1±17.0 −0.059 0.649
FEV1 (%pred) 81.9±23.9 −0.045 0.726
Chronic Pseudomonas aeruginosa colonization Yes 15 (23) 7.81±6.61 0.062
No 51 (77) 4.98±2.63
Pancreatic insufficiency Yes 58 (88) 5.86±4.23 0.049
No 8 (12) 3.95±0.55
Biometrics Length (z-score) −0.61±1.18 −0.055 0.659
Weigth (z-score) −0.59±1.14 −0.190 0.127
BMI (z-score) −0.27±1.00 −0.221 0.075
Liver stiffness values are reported (mean±standard deviation) or in the case of continuous variables the Spearman correlation coefficient.
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liver stiffness measurements (13.6, 20.5 and 29.1kPa) had
esophageal varices. One patient with a liver stiffness of 11.6kPa
(patient 8) underwent liver biopsy which showed periportal
fibrosis and an occasional portoportal septum.
Liver stiffness measurements were significantly higher in the
patient group with clinical liver disease (palpable hepatomegaly
or splenomegaly) (11.07±5.51kPa (n=6) versus 5.08±3.45kPa
(n=60) , pb0.0001), in the patient group with biochemical CFLD
(7.40±3.10kPa (n=7) versus 5.42±4.08kPa (n=59), p=0.013),
in the patient group with abnormal ultrasound (Williams
score≥ 4: 8.19 ± 5.96 kPa (n=23) versus 4.27 ± 0.94 kPa
(n=41), pb0.0001) and also in the group with splenomegaly as
detected on ultrasound (9.10±6.78kPa (n=16) versus 4.54±
1.49kPa (n=48), pb0.0001). There was a significant correlation
with the clinician's perceived probability of liver cirrhosis
(R=0.268, p=0.030).
3.4. Liver stiffness and the CFF consensus definition
Using the CFF consensus definition the Fibroscan has a
sensitivity of 63%, a specificity of 87%, a positive likelihood
ratio of 5.00 and a negative likelihood ratio of 0.42. ROC
analysis revealed an AUC of 0.858 (see Fig. 2 and Table 3). The
Williams score for the detection of ultrasonographic CFLD has
a lower AUC of 0.700. The ROC curve of the APRI score as
non-invasive marker of liver disease was not significantlydifferent from 0.500 (p=0.908). A more detailed comparison of
the diagnostic accuracy of ultrasound and Fibroscan in the
detection of CFLD in shown in Table 3. This shows that
Fibroscan is not inferior or superior to ultrasound in the
detection of CFLD in this patient population.
In the patient group with an abnormal Fibroscan result 7/14
patients do not have CFLD according to the CFF definition
(patients 2–5, 7, 9, 11 see Table 2 and see Fig. 3). However, all
of these patients had abnormalities on hepatic ultrasound.
Moreover, there was even one patient with suspected cirrhosis
on ultrasound (patient 7).
On the other hand, there were 4 patients with CFLD
according to the CFF definition (clinical or biochemical
abnormalities) who had normal Fibroscan results (i.e. below
the age-specific cut-off). One of these patients had clinical
CFLD (clinical hepatomegaly, which could not be confirmed on
ultrasound) and 3 had biochemical CFLD. All had normal
hepatic ultrasound (Williams score b4/9, i.e. normal liver edge,
parenchyma and periportal findings).
3.5. Associated factors with CFLD (See Table 1)
The traditionally recognized risk factors (genotype group,
age, age at diagnosis, pancreatic insufficiency and history of
meconium ileus) identified by ultrasound Williams score
(pb0.05 for all), were also identified by the Fibroscan (See
Table 1).
Table 2
Characteristics of patients with abnormal liver stiffness measurements.
Pat.
Nr
age Sex Stiffness IQR Clinical findings Abnormal liver
tests
Williams score,
hepatomegaly or
splenomegaly
Gastroscopy
findings
FVC FEV1 Weight Length BMI UDCA Genotype Age at
diagn
PI MI Chronic
Ps. aer.(yr) (m/f) (kPa) (kPa)
%
pred
%
pred
z-score z-score z-score
1 3.0 f 7.5 2.7 Hepatomegaly and
splenomegaly
AST, ALT,
Bilirubin, GGT
3, splenomegaly – – – −1.5 −0.6 −1.8 Sometimes F508del /
F508del
0.3 Yes No Yes
2 6.9 m 5.7 1.2 Normal None 5, hepatomegaly and
splenomegaly
Normal 108.0 111.0 −0.8 0.0 −1.3 Never F508de l /
F508del
0.7 Yes No No
3 8.6 m 5.7 1.3 Normal None 6, hepatomegaly and
splenomegaly
– 106.0 103.0 0.9 0.7 0.8 Sometimes F508del /
F508del
0.1 Yes No No
4 9.9 m 10.8 2.6 Normal None 5, hepatomegaly and
splenomegaly
– 90.0 93.0 −0.9 −0.5 −0.9 Sometimes F508del /
F508del
0.0 Yes Yes No
5 11.5 m 6.1 1.7 Normal None 4, normal liver and
spleen size
– 85.0 88.0 0.6 −0.4 1.0 Never F508de l /
F508del
0.0 Yes Yes No
6 12.6 m 20.5 3.8 Hepatomegaly and
splenomegaly
None 7–9, hepatomegaly and
splenomegaly
Esophageal
varices
76.0 48.0 0.1 0.0 0.2 Sometimes F508del /
N1303K
4.3 Yes No No
7 15.5 f 29.1 6.5 Normal None 9, liver cirrhosis,
splenomegaly
Esophageal
varices
102.0 102.0 −2.6 −1.7 −1.8 Sometimes F508del /
F508del
0.0 Yes Yes Yes
8 15.7 f 11.6 3.4 hepatomegaly None 5, hepatomegaly Normal 64.0 51.0 −2.9 −2.6 −1.4 Sometimes F508del /
F508del
0.2 Yes No Yes
9 16.1 m 6.6 1.9 Normal None 4, splenomgaly – 95.0 87.0 −3.7 −3.0 −2.3 Never F508de l /
F508del
4.8 Yes No No
10 16.6 f 7.5 1.3 Normal AST, ALT,
GGT
4, normal liver and
spleen size
Normal 99.0 100.0 1.0 0.7 0.9 Never F508de l /
F508del
0.1 Yes No Yes
11 16.7 m 8.1 2.8 Normal None 5, hepatomegaly – 112.0 115.0 −1.0 −1.0 −0.5 Sometimes F508del /
F508del
1.1 Yes No No
12 23.2 f 7.9 1.4 Splenomegaly None 9, liver cirrhosis,
splenomegaly
– 78.0 73.0 −0.7 −0.6 −0.5 Sometimes F508del /
F508del
0.1 Yes Yes Yes
13 29.1 m 7.9 3.0 Normal AST, ALT 4, steatosis,
hepatomegaly and
splenomegaly
– 73.0 39.0 0.9 0.5 0.7 Sometimes F508del /
F508del
0.1 Yes No No
14 29.8 f 13.6 2.4 Splenomegaly Alkaline
phosphatase,
ALT, GGT
9, liver cirrhosis,
splenomegaly
Esophageal
varices
64.0 33.0 −3.0 −2.8 −1.2 Sometimes F508del /
F508del
0.0 Yes Yes Yes
Abbreviations:
BMI: body mass index, Diagn: diagnosis, f: female, FEV1: one second forced expiratory volume, FVC: forced vital capacity, IQR: interquartile range, m: male, MI: meconium ileus, Pat Nr: patient number, PI: pancreatic
insufficiency, %pred: percentage of predicted, Ps. aer: Pseudomonas aeruginosa, UDCA: ursodeoxycholic acid.
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Fig. 2. ROC curve analysis for Fibroscan result, Williams score and APRI test
against CFLD CFF definition. Area for Fibroscan 0.858 (95%CI: 0.738–0.977,
pb0.001) versus area for Williams score 0.700 (95%CI: 0.512–0.888,
p=0.038) and APRI score 0.511 (95%CI: 0.299–0.724, p=NS).
Fig. 3. CFLD CFF definition and liver stiffness measurements with selected
ultrasound findings. US: Ultrasound.
397P. Witters et al. / Journal of Cystic Fibrosis 8 (2009) 392–399In addition, there was a significant negative correlation with
the platelet count (R=−0.256, p=0.038) and a positive
correlation with the mean platelet volume (R= 0.329,
p=0.007). There was no correlation with the APRI-score
(p=0.169).
4. Discussion
Several studies have attempted to adequately screen for
CFLD, but all have failed [19]. Developing new screening tools
for the detection of CFLD is problematic, because there is no
universally accepted definition of CFLD, classic non-invasiveTable 3
Diagnostic accuracy of a) ultrasound and b) Fibroscan in the detection of clinical
and/or biochemical liver disease.
CFLD
definition used
Sensitivity
(%)
Specificity
(%)
ROC analysis
AUC 95% C.I. p-value
A) Diagnostic accuracy of ultrasound
Clinical CFLD 67 67 0.766 0.509–1.022 0.033
Biochemical CFLD 57 67 0.618 0.398–0.838 NS (0.312)
Clinical or
Biochemical CFLD
64 70 0.700 0.512–0.888 0.038
Clinical and
Biochemical CFLD
50 65 0.661 0.171–1.152 NS (0.44)
B) Diagnostic accuracy of Fibroscan
Clinical CFLD 83 85 0.928 0.849–1.008 0.001
Biochemical CFLD 57 83 0.781 0.613–0.949 0.016
Clinical or
Biochemical CFLD
63 87 0.858 0.738–0.977 b0.001
Clinical and
Biochemical CFLD
100 81 0.923 0.837–1.009 0.043
Abbreviations: CFLD: Cystic fibrosis associated liver disease.assessments of liver fibrosis are not validated for a paediatric
population and several CF-associated processes can cloud the
diagnosis (i.e. CF is a multisystemic disease whereby other
processes e.g. infection and medication can modify classic non-
invasive markers of liver disease (e.g. AST levels)) [3]. To our
knowledge this is the first study to solely investigate the use of
the Fibroscan in an unselected population of CF patients and
relate the elasticity to the special characteristics of CFLD.
In this study we have shown that the use of the Fibroscan is
feasible in CF patients. One examination (10 measurements)
takes under five minutes and is feasible even in young patients.
Moreover, in contrast to its use in paediatric NASH [15] the
investigation is facilitated due to the pulmonary hyperinflation
enlarging the intercostal space and the non-obesity of these
patients.
Defining clinically significant liver disease is highly
problematic [3]. It is defined according to the CFF definition
on the basis of clinical findings or abnormal biochemistry [3]. It
has been shown that diagnosing CFLD on the basis of clinical
findings of hepatomegaly or splenomegaly has a sensitivity of
only 42% and 57% and a specificity of 72% and 72%
respectively compared to histology [20]. Likewise, an elevated
ALT or GGT have a low sensitivity of 52 and 50% and a
specificity of 77 and 74% respectively [20]. This makes it
questionable to calculate the sensitivity or specificity compared
to this definition (the gold standard) and could lead to an under-
or overestimation of the diagnostic accuracy of the technique
that is being evaluated. Nevertheless, the Fibroscan compares at
least equal to ultrasound in a ROC curve analysis in reference to
the CFF definition (see Fig. 2). In the present series there is a
sensitivity of 63% and a specificity of 87%. Six patients were
detected that did not fulfill the definition of CFLD (CFF
definition), while all of these patients did also have ultrasono-
graphic evidence of CFLD and could have CFLD. One of these
patients was categorized as probably having cirrhosis on
ultrasound (patient 7, see Table 2).
Although there is no clear difference in performance of
the Fibroscan and of ultrasound in the detection of fibrosis
in this particular study for this particular cohort of CF patients
398 P. Witters et al. / Journal of Cystic Fibrosis 8 (2009) 392–399(see Table 3), Fibroscan has proven to have excellent inter-
and intra-observer, intersite and interequipment agreements
and overall superiority in the detection of fibrosis, when com-
pared to ultrasound [21]. It is easy to learn, independent of
professional training (i.e. a nurse could do it) [22]. The price of
the Fibroscan apparatus is 70,000 euro, which is clearly more
expensive than an ultrasound apparatus (15,000 euro for one
probe, no doppler). Ultrasound has the advantage that it can
detect more abdominal abnormalities than only liver fibrosis,
although the significance of these occasional findings is unclear
[23].
No extensive anatomopathologic investigations were under-
taken here. In CFLD, liver biopsy is known to be unreliable, due
to the focal nature of CFLD [3]. So, biopsy should be guided by
ultrasound in an attempt to obtain a representative sample, i.e.
not in the most or least affected region [20]. Otherwise there
would be an over- or underestimation of the total degree of liver
disease. Moreover, since there are over 50 reports [12] con-
firming the close relation between the liver stiffness and degree
of fibrosis (also in focal liver diseases characterized by biliary
fibrosis as PBC and PSC) the question is raised whether it is
ethical to perform a study comparing Fibroscan to histology in a
mainly paediatric CF population. A longitudinal follow-up of
the here described cohort will clarify the evolution and the
development of clinical CFLD in the patients with abnormal
liver stiffness measurements.
It should be noted that all examined patients were present-
ing at the consultation in their usual state of health. This is
important, as it is known that liver stiffness measurement in the
setting of acute hepatitis (with a flare of transaminases), acute
liver damage or extrahepatic cholestasis in jaundiced patients
gives rise to an overestimation of the degree of liver fibrosis
[24].
Although not the main goal of this study, similar risk factors
can be found using the Fibroscan compared to other modes of
detection of CFLD (clinical, biochemical, ultrasonographical).
We have found that genotype [4,6,8], age at diagnosis [9], age
(at evaluation) [6,8], past medical history of meconium ileus
[1,4,9] and pancreatic insufficiency [1,6] are risk factors in the
development of CFLD in the studied population, which is in
accordance with the current literature.
Currently, proof of effective therapies or preventive measures
for CFLD is lacking. Partly this can be because of problems with
the detection and definition of CFLD. Ursodeoxycholic acid is
to date the only accepted treatment for CFLD [25], although
improvement in clinically significant endpoints remains to be
demonstrated [26]. In analogy to PBC, ursodeoxycholic acid
could prove to be of benefit if given at sufficient dose and more
importantly early enough. This requires early and reproducible
diagnosis and non-invasive reliable follow-up endpoints. In the
future, with the advent of antifibrotic therapies, fibroscan could
also prove useful to screen for developing fibrosis.
In conclusion, CFLD is difficult to screen and diagnose with
the current modes of detection. We have shown that Fibroscan is
an easy, fast and non-invasive examination that could contribute
to the early detection of CFLD. Further studies are needed to
determine its role in the management of CFLD.Conflict of interest
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